Literature DB >> 20085583

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

Niels W C J van de Donk, Shulamit Wittebol, Monique C Minnema, Henk M Lokhorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20085583     DOI： 10.1111/j.1365-2141.2009.07931.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

Authors:  N Shah; P F Thall; P S Fox; Q Bashir; J J Shah; S Parmar; P Lin; P Kebriaei; Y Nieto; U R Popat; C M Hosing; A Cornelison; E J Shpall; R Z Orlowski; R E Champlin; M H Qazilbash
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

Review 2.  Management of multiple myeloma in the relapsed/refractory patient.

Authors:  Pieter Sonneveld
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Authors:  J Laubach; L Garderet; A Mahindra; G Gahrton; J Caers; O Sezer; P Voorhees; X Leleu; H E Johnsen; M Streetly; A Jurczyszyn; H Ludwig; U-H Mellqvist; W-J Chng; L Pilarski; H Einsele; J Hou; I Turesson; E Zamagni; C S Chim; A Mazumder; J Westin; J Lu; T Reiman; S Kristinsson; D Joshua; M Roussel; P O'Gorman; E Terpos; P McCarthy; M Dimopoulos; P Moreau; R Z Orlowski; J S Miguel; K C Anderson; A Palumbo; S Kumar; V Rajkumar; B Durie; P G Richardson
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

Review 4.  Novel agents and new therapeutic approaches for treatment of multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Angelo Vacca
Journal:  World J Methodol       Date:  2014-06-26

Review 5.  A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Authors:  B Franken; N W C J van de Donk; J C Cloos; S Zweegman; H M Lokhorst
Journal:  Ther Adv Hematol       Date:  2016-09-13

6.  Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.

Authors:  Nilanjan Ghosh; Noah Tucker; Marianna Zahurak; Jocelyn Wozney; Ivan Borrello; Carol Ann Huff
Journal:  Am J Hematol       Date:  2014-04-26       Impact factor: 10.047

Review 7.  Treatment of relapsed and refractory multiple myeloma.

Authors:  Pieter Sonneveld; Annemiek Broijl
Journal:  Haematologica       Date:  2016-04       Impact factor: 9.941

8.  Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

Authors:  Niels Wcj van de Donk; Güllü Görgün; Richard Wj Groen; Jana Jakubikova; Constantine S Mitsiades; Teru Hideshima; Jacob Laubach; Inger S Nijhof; Reinier A Raymakers; Henk M Lokhorst; Paul G Richardson; Kenneth C Anderson
Journal:  Cancer Manag Res       Date:  2012-08-14       Impact factor: 3.989

9.  Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide.

Authors:  Shigeki Ito; Tatsuo Oyake; Kazunori Murai; Yoji Ishida
Journal:  Case Rep Hematol       Date:  2013-03-28

Review 10.  The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.

Authors:  Maximilian Merz; Tobias Dechow; Mithun Scheytt; Christian Schmidt; Bjoern Hackanson; Stefan Knop
Journal:  Ann Hematol       Date:  2020-04-16       Impact factor: 3.673
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.